ADENOSINE RECEPTOR ANTAGONISTS AND COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF DISEASE ASSOCIATED WITH EXPRESSION OF AT LEAST ONE ANTIBODY-SECRETING CELL MARKER

The present disclosure relates to treatment of a subject who has been identified with an increased IRF4 gene expression or infiltration of MUM-1+ cells. The present disclosure also relates to treatment of a subject who has been identified with an increased gene expression of at least one antibody-se...

Full description

Saved in:
Bibliographic Details
Main Authors ROSS, Sally, ROSSETTI, Maura, MARTINOLI, Chiara, WALD, Noemie, LAGER, Joanne
Format Patent
LanguageEnglish
French
Published 22.02.2024
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to treatment of a subject who has been identified with an increased IRF4 gene expression or infiltration of MUM-1+ cells. The present disclosure also relates to treatment of a subject who has been identified with an increased gene expression of at least one antibody-secreting cell (ASC) marker or infiltration of cells positive for at least one ASC marker. La présente divulgation concerne le traitement d'un sujet dont on a identifié une augmentation de l'expression du gène IRF4 ou une infiltration de cellules MUM-1+. La présente divulgation concerne également le traitement d'un sujet ayant été identifié avec une expression génétique accrue d'au moins un marqueur de cellules sécrétrices d'anticorps (ASC) ou une infiltration de cellules positives pour au moins un marqueur d'ASC.
Bibliography:Application Number: WO2023US72187